Company Overview and News


Add RHHBY
to your dashboard

Headline News

Genentech drugs successful in Roche studies

2017-11-21 sfgate
Roche Holding shares rose this week after experimental medicines for cancer and hemophilia, both developed by Roche unit Genentech of South San Francisco, succeeded in much-anticipated patient trials, boding well for the Swiss drugmaker’s ability to grow. (87-0)

Roche Reports Positive Data From Tecentriq Combination Study

2017-11-20 zacks
Roche Holding AG’s (RHHBY - Free Report) member, Genentech, announced that the phase III IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin has met its co-primary endpoint of progression-free survival (PFS). The study is being conducted  in people with stage IV non-squamous non-small cell lung cancer (NSCLC), who had not been treated with chemotherapy for their advanced disease. (51-0)

Tracking Tweedy Browne Portfolio - Q3 2017 Update

2017-11-20 seekingalpha
The largest five individual stock positions are Cisco Systems, Berkshire Hathaway, Baidu Inc., Johnson & Johnson, and Alphabet, and they account for ~44% of the portfolio. (558-0)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

This $5 Billion Startup Made Its First Cancer Vaccine—For Just One Person - Bloomberg

2017-11-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (15-0)

Shire Gets Positive CHMP Opinion for Hemophilia A Drug

2017-11-14 zacks
Shire plc (SHPG - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has issued a positive opinion recommending approval  of Adynovi [Antihemophilic Factor (Recombinant), PEGylated]. (73-0)

Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

2017-11-10 zacks
Merck KGaA reported third-quarter 2017 earnings of $1.77 per American Depositary Share, 6.4% lower than the year-ago figure of $1.90. (104-0)

Regeneron's Long-Term Issues Linger - Bloomberg Gadfly

2017-11-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (114-0)

3Q17 Performances for Roche’s Tecentriq and Alecensa

2017-11-06 marketrealist
In 3Q17, Roche Holding’s (RHHBY) Tecentriq generated revenues of 118 million Swiss francs, which reflected ~104% growth on a year-over-year (or YoY) basis and a 5% fall on a quarter-over-quarter (or QoQ) basis. In 3Q17 in the US and European markets, Tecentriq generated revenues of 112 million Swiss francs and 2 million Swiss francs, respectively, which reflected ~99% and ~130% growth, respectively, YoY. (89-0)

US FDA approves Roche drug for rare type of blood cancer - Channel NewsAsia

2017-11-06 channelnewsasia
Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer. (15-0)

A Look at Roche’s New Drug Ocrevus in 3Q17

2017-11-06 marketrealist
In 3Q17, Roche Holding (RHHBY) generated revenues of 13.1 billion Swiss francs, which was a ~5% rise YoY (year-over-year). Its Pharmaceuticals segment generated revenues of 10.1 billion Swiss francs, which reflected a ~4% rise YoY. Its Diagnostics segment generated revenues of 3.0 billion Swiss francs, which was a ~6% rise YoY. (15-0)

U.S. FDA approves Roche drug for rare type of blood cancer

2017-11-06 reuters
Nov 6 (Reuters) - Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer. (15-0)

Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

2017-11-02 zacks
Immune Design Corp. (IMDZ - Free Report) reported loss of 52 cents per share in the third-quarter 2017, narrower than the Zacks Consensus Estimate of a loss of 63 cents and also a year-ago loss of 60 cents. (22-0)

Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales

2017-11-02 zacks
Exelixis, Inc. (EXEL - Free Report) reported impressive results for third-quarter 2017 on the back of increased Cabometyx sales. The company posted third-quarter 2017 earnings of 26 cents, beating the Zacks Consensus Estimate of 8 cents. Notably, the company reported a loss of 4 cents per share in the year-ago quarter. (121-0)

What's in the Cards for Prothena (PRTA) in Q3 Earnings?

2017-10-31 zacks
Prothena Corporation plc (PRTA - Free Report) is expected to report third-quarter 2017 results on Nov 7. (91-0)

CUSIP: 771195104